Medical Research Center, The University of Tennessee, Knoxville, USA
Research Article
Peptide-mRNA Vaccine for SARS-Cov-2
Author(s): Esmaeil Farshi*
A vaccine is described which elicits a protective immune response against SARS-Cov-2. Designed engineered peptides that could strongly bind to the spike protein of coronavirus inside cells, and to use these peptides to trigger the cells to break down the viral proteins. In this vaccine the mRNA (encoding Ribonucleic Acid) encodes a stable perfused form (the form before being fused to the cell membrane of the host cell) of Spike protein (S). In this vaccine the main problem of short time remaining of antibodies of SARS-Cov-2 virus in body could be compensated by activation of T cells that causes long term immunity because memory T cells remain in body at least 11 years. A peptide based vaccine with encoding mRNA of virus along the activation of T cells through MHC class-II which elicits protection against SARS-Cov-2 through immune cells from the lymph nodes process the mRNA and synthes.. View more»